{"id":11378,"date":"2023-06-27T13:13:04","date_gmt":"2023-06-27T05:13:04","guid":{"rendered":"https:\/\/medicine.nus.edu.sg\/cbme\/?page_id=11378"},"modified":"2023-07-19T10:37:17","modified_gmt":"2023-07-19T02:37:17","slug":"research-infrastructures-as-quality-improvement-interventions","status":"publish","type":"page","link":"https:\/\/medicine.nus.edu.sg\/cbme\/research-infrastructures-as-quality-improvement-interventions\/","title":{"rendered":"Research Infrastructures as Quality Improvement Interventions"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n

Venue: Auditorium, Blk MD 11, 10 Medical Drive Singapore 117597 | In-person<\/o:p><\/span><\/strong><\/p>\n

Date: Wednesday 23 August 2023<\/o:p><\/span><\/strong><\/p>\n

Time: 4.30PM to 5.30PM<\/o:p><\/span><\/strong><\/p>\n

<\/p>\n

\n<\/p>

\n
\n

\n<\/p><\/div>\n<\/div>\n<\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Synopsis<\/h4>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Standard accounts of research ethics are based upon the idea that, by accepting risks today, study participants<\/span> <\/span>contribute to generalizable knowledge that may benefit future patients. In other words, participants bear the risks today, whereas benefits don\u2019t accrue until a future time. However, there are both empirical and theoretical reasons to believe that building research infrastructures can have immediate benefits for patients today, including both those who take part in the research and those who just receive care from participating institutions. Furthermore, the short-term benefits of research infrastructures may have particular impact in low and middle income countries.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Speaker's Biography<\/h4>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
Professor Steven Joffe<\/h6>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Art and Ilene Penn Professor of Medical Ethics and Health Policy
and Chair of the Department of Medical Ethics and Health Policy, Perelman School of Medicine,
University of Pennsylvania.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
Biography<\/h6>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Steven Joffe, MD, MPH is a pediatric oncologist and bioethicist who is currently the Art and Ilene Penn Professor and Chair of the Department of Medical Ethics & Health Policy, and Professor of Pediatrics, at the University of Pennsylvania Perelman School of Medicine. \u00a0He is also the Director of the\u00a0Penn Postdoctoral Training Program in the Ethical, Legal and Social Implications (ELSI) of Genetics and Genomics.<\/span><\/p>\n

Dr. Joffe’s research addresses the many ethical challenges that arise in the conduct of clinical and translational investigation.\u00a0\u00a0He has led NIH-, PCORI- and foundation-funded projects to study the roles and responsibilities of principal investigators in multicenter randomized trials, accountability in the clinical research enterprise, children\u2019s capacity to engage in research decisions, return of individual genetic results to participants in epidemiologic cohort studies, the integration of whole-exome sequencing technologies into the clinical care of cancer patients, strategies for diagnosis of germline risk among young adults with cancer, and the nature and challenges of learning health systems. He has coauthored over 200 articles addressing these topics. \u00a0He previously served as a member of the US Department of Health and Human Services Coronavirus Disease 2019 (COVID-19) Vaccine Data and Safety Monitoring Board and chaired the National Human Genome Research Institute\u2019s Genomics and Society Working Group. He is an elected member of the US National Academy of Medicine.<\/o:p><\/span><\/p>\n

Dr. Joffe attended Harvard College, received his medical degree from the University of California at San Francisco, and received his public health degree from UC Berkeley.\u00a0 He trained in pediatrics at UCSF and undertook fellowship training in pediatric hematology\/oncology at the Dana-Farber Cancer Institute and Boston Children\u2019s Hospital.<\/o:p><\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Venue Map<\/h4>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t